Understanding Vitreomacular traction
The vitreous is the gel occupying the back of the eye. Its separation from the retina is often part of aging, but persistent focal attachment can pull on the macula. VMT means this attachment is accompanied by structural distortion; attachment without such distortion is termed vitreomacular adhesion. [1] [2]
Symptoms and course vary. Some traction releases without an intervention, some remains stable and some progresses or is associated with a macular hole. Decisions consider the OCT findings, the person’s visual tasks and the risks of intervention rather than the mere presence of an attachment. [2] [3]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Straight lines bend
Central traction can make a line appear wavy or an object look distorted. A task such as reading or looking at a doorframe may reveal the problem more clearly than a single acuity score. [1]
Reduced central clarity
Blur, smaller-looking objects or a central patch can occur. These complaints overlap with other macular disorders; their appearance alone does not show how firmly the vitreous is attached. [1] [6]
Symptoms and OCT can differ
Visible traction may be less troublesome in one person than another. An anatomical change or release is important, but does not by itself explain reading comfort or prove that all vision will normalize. [2] [4]
Attachment is not always traction
Original simplified interface schematic; no scale measurement, surgical instruction or prognosis calculator. [1] [2] [3]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Separation
The vitreous starts separating from the central retina.
- Persistent pull
Remaining attachment may deform the foveal contour.
- Clinical choice
Symptoms, OCT and risks guide monitoring or intervention.
What is happening—and what remains uncertain
During posterior vitreous separation, adhesion can persist at the fovea. The remaining attachment exerts traction on retinal layers, changing the foveal contour or creating cyst-like spaces. OCT displays this relationship in cross-section rather than inferring it from a blur description. [1] [6]
An epiretinal membrane can coexist and alter forces at the interface. Persistent traction may contribute to a full-thickness macular hole, but VMT and a hole are distinct findings and require separate characterization when both are present. [2] [6]
What can look similar?
Adhesion versus traction
Vitreomacular adhesion describes attachment without the retinal distortion needed for VMT. A scan label should be interpreted alongside its morphology and symptoms rather than automatically trigger surgery. [2]
Traction versus epiretinal membrane
An epiretinal membrane is tissue on the retinal surface; VMT involves a pulling vitreous attachment. They can coexist but are not the same structure or necessarily the same management problem. [2]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Connect the scan with the taskExplain which eye and activity are affected, the onset and whether symptoms are changing. The team considers function, fellow-eye vision and the person’s goals alongside the retinal appearance. [2]
- Use OCT to define the interfaceOCT shows attachment width, retinal distortion, associated membrane and whether a hole or fluid is present. Measurements can help characterize prognosis, but published predictors of spontaneous release are not guarantees. [3] [6]
- Agree monitoring and return adviceIf observation is appropriate, ask when repeat examination and OCT are planned and which changes should trigger earlier contact. Observing VMT means an active follow-up plan, not ignoring a new visual event. [2] [3]
What may help—and what is still being studied
Observation may be appropriate
A systematic review found spontaneous release in a subset of observed eyes, with smaller attachment width and absent epiretinal membrane among associated features. Follow-up duration and selection varied, so a pooled percentage should not be treated as a personal forecast. [3]
Vitrectomy has functional goals and risks
Surgery can remove the pulling vitreous when the expected benefit justifies it. Discuss cataract progression, retinal tear or detachment, infection and incomplete symptom recovery, including whether any gas bubble would change travel or anesthetic precautions. [1] [2]
Check the status of injection alternatives
The DRCR gas-injection protocols stopped early because of retinal tears and detachments despite frequent anatomical release. Ocriplasmin had trial efficacy in selected eyes, but Jetrea’s EU authorization was withdrawn for commercial reasons and NICE withdrew its guidance; old availability statements need checking locally. [4] [5] [7] [8]
What this can mean for daily life
Track meaningful change
Use a consistent ordinary reading task to describe what has changed, following the clinician’s monitoring advice. Matching a simulator setting does not measure attachment strength or establish that release has occurred. [2] [6]
Reduce the burden of detail tasks
Discuss text magnification, accessible digital material and low-vision advice if distortion interferes with work or reading. Rehabilitation can be useful while a decision about intervention is still being made. [10]
Prepare around a procedure
If a gas bubble is used, obtain explicit instructions about flying, altitude and nitrous-oxide anesthesia until the surgeon confirms it has gone. Do not assume every VMT procedure uses the same gas or restrictions. [9]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
Predictive factors of spontaneous VMT release
Spontaneous release occurred in 272 eyes across the included follow-up periods; smaller attachment width and absent epiretinal membrane were associated with release. [3]
Limits and applicability: Predominantly observational data, variable follow-up and limited predictor samples. Associations and pooled event proportions are not personal probabilities or proof that waiting is best for every eye.
DRCR Retina Network protocols AG and AH
Gas injection produced more VMT release than sham in AG without a significant acuity advantage; 7 of 59 treated eyes across protocols had retinal tear or detachment, prompting early termination. [4]
Limits and applicability: Small samples and early stopping produce imprecise safety estimates. AH was not randomized, and anatomy, acuity and complications must be considered separately.
MIVI-TRUST ocriplasmin trials
Day-28 attachment release was more frequent with ocriplasmin than placebo, with more reported ocular adverse events. [5]
Limits and applicability: Selected eligibility, short anatomical primary endpoint and older availability context. Trial evidence is not proof the product remains marketed or is preferable to surgery now.
Questions researchers still need to answer
- Which combination of symptoms, retinal integrity and interface anatomy best predicts useful visual recovery after release?
- Can safer alternatives achieve durable functional benefit rather than anatomical release alone?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
ASRS — vitreomacular traction
Patient explanation of the vitreous–macula interface, imaging and management questions; verify injection availability against current local sources.
Macular Society — central-vision support
Broader macular helpline, practical advice and local peer support for central visual difficulty. Not a VMT-only treatment service.
Connections listed by the organization.
AAO — 2025 ERM and VMT Preferred Practice Pattern
Detailed guidance useful for specialist discussions about symptoms, scans and intervention.
NICE — withdrawn ocriplasmin guidance
Official withdrawal notice helps explain why older treatment pages may list a medicine no longer marketed in the UK.
Questions you may still have
Does every attachment need treatment?
No. Adhesion without distortion is not the same as VMT. Even true traction may be monitored when symptoms and retinal findings support observation. [2] [3]
Can it release on its own?
Yes, in some eyes. Studies describe associations with anatomy, but release timing and visual improvement remain variable. Keep the agreed follow-up plan. [3]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- ASRS — Vitreomacular Traction Syndrome (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - AAO — Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern (2025; guideline).
Indexed original guideline body checked; direct publisher 403. April 2025 issue.
Checked 2026-10-24 · Full text checked - Garg et al. — Predictive Factors of Spontaneous Release of Vitreomacular Traction (2022; systematic review).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Chan et al. — Pneumatic Vitreolysis: DRCR Protocols AG and AH (2021; trial).
Complete indexed abstract read. Randomized AG and single-arm AH distinguished, combined safety denominator 59 treated eyes.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Stalmans et al. — Enzymatic vitreolysis with ocriplasmin (2012; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Vitreomacular traction — a review (2025; review).
Indexed original clinical review read; direct PMC challenge. Regulatory availability checked independently.
Checked 2026-10-24 · Full text checked - EMA — Jetrea withdrawal (2025; institution).
Official page records EU withdrawal August 30, 2023 at holder request for commercial reasons. English URL rate-limited; indexed French page with English withdrawal text checked.
Checked 2026-10-24 · Public page checked - NICE TA297 — Ocriplasmin guidance withdrawn (n.d.; institution).
Indexed official withdrawal statement checked; direct request 403.
Checked 2026-10-24 · Public page checked - NHS — Macular hole (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - Macular Society — support and practical information (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - NHS — Vision loss (n.d.; institution).
Official sudden sight-loss/severe pain emergency versus other urgent visual-change guidance checked; local service routes vary internationally.
Checked 2026-10-24 · Public page checked - NEI — Retinal detachment warning signs (n.d.; institution).
Official new flashes/floaters/curtain warning signs and immediate eye-doctor or emergency assessment checked; a prior retinal diagnosis does not exclude a new acute problem.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.